IAC Inc. (BIT:1IAC)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,094	1,798	1,297	1,417	2,119	3,366
Short-Term Investments	-	-	149	239.37	19.79	224.98
Cash & Short-Term Investments	1,094	1,798	1,446	1,657	2,139	3,591
Cash Growth	-35.23%	24.32%	-12.70%	-22.53%	-40.45%	327.62%
Accounts Receivable	376.19	519.69	536.65	607.81	695.51	257.67
Receivables	376.19	519.69	536.65	607.81	695.51	257.67
Inventory	-	-	-	-	-	0.32
Prepaid Expenses	-	51.8	91.12	80.04	73.48	46.1
Restricted Cash	1.71	-	-	-	-	0.45
Other Current Assets	129.81	115.37	166.38	216.52	168.71	223.64
Total Current Assets	1,602	2,485	2,241	2,561	3,076	4,119
Property, Plant & Equipment	304.74	647.94	754.88	938.77	1,069	445.08
Long-Term Investments	2,705	2,733	3,353	2,543	3,087	2,163
Goodwill	1,993	2,877	3,024	3,030	3,227	1,660
Other Intangible Assets	507.53	722.14	874.71	1,170	1,415	394.99
Long-Term Deferred Charges	-	3.61	6.06	5.67	6.09	4.4
Other Long-Term Assets	247.8	78.82	117.98	145.15	423.35	374.74
Total Assets	7,360	9,547	10,371	10,394	12,303	9,162
Accounts Payable	47.86	71.99	105.51	133.11	203.17	88.85
Accrued Expenses	424.73	262.1	236.44	247.83	346.4	163.57
Current Portion of Long-Term Debt	21	35	30	30	30	-
Current Portion of Leases	-	62.06	68.13	67.19	63.52	27.14
Current Unearned Revenue	65.06	98.57	143.45	157.12	165.45	137.66
Other Current Liabilities	-	356.48	366.96	444.74	572.95	333.69
Total Current Liabilities	558.65	886.19	950.49	1,080	1,382	750.9
Long-Term Debt	1,414	1,932	1,994	2,020	2,046	712.28
Long-Term Leases	-	344.65	401.12	518.85	578.27	205.36
Long-Term Unearned Revenue	0.1	0.1	0.1	0.2	0.4	0.7
Long-Term Deferred Tax Liabilities	134.82	13.87	164.61	76.28	385.89	78.79
Other Long-Term Liabilities	290	66.11	72.42	98.79	142.59	30.76
Total Liabilities	2,398	3,243	3,583	3,794	4,535	1,779
Common Stock	0.01	0.01	0.01	0.01	0.01	0.09
Additional Paid-In Capital	5,920	6,381	6,340	6,295	6,266	5,910
Retained Earnings	-544.33	-538.97	0.92	-265.02	905.15	694.04
Treasury Stock	-453.97	-252.44	-252.44	-85.32	-	-
Comprehensive Income & Other	-11.1	-11.4	-10.94	-13.13	4.4	-6.17
Total Common Equity	4,911	5,578	6,078	5,932	7,175	6,598
Minority Interest	51.69	726.49	710.52	668.16	592.48	785.35
Shareholders' Equity	4,963	6,304	6,788	6,600	7,768	7,383
Total Liabilities & Equity	7,360	9,547	10,371	10,394	12,303	9,162
Total Debt	1,435	2,374	2,493	2,636	2,718	944.78
Net Cash (Debt)	-341.18	-575.39	-1,047	-979.04	-579.51	2,646
Net Cash Growth	-	-	-	-	-	557.33%
Net Cash Per Share	-4.14	-6.92	-12.11	-11.34	-6.31	29.10
Filing Date Shares Outstanding	80.16	83.28	85.97	88.87	89.76	88.77
Total Common Shares Outstanding	79.9	86.27	85.9	88.87	89.71	88.77
Working Capital	1,043	1,599	1,290	1,481	1,695	3,368
Book Value Per Share	61.47	64.66	70.75	66.74	79.98	74.33
Tangible Book Value	2,410	1,979	2,179	1,731	2,534	4,542
Tangible Book Value Per Share	30.17	22.94	25.36	19.48	28.24	51.17
Land	-	86.05	86.03	20.23	33.92	-
Buildings	-	165.7	160.57	305.3	418.25	195.5
Machinery	-	136.88	160.99	137.57	181.61	83.5
Construction In Progress	-	40.19	13.91	30.38	47.22	53.64
Leasehold Improvements	-	92.32	108.27	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.